Xconomy: For Those on Watch, Hope Springs Eternal as Hair Trials Inch Along
Summary
An additional physician-sponsored investigational new drug (IND) study is being conducted in the United States by Dr. Craig Ziering with 10 subjects, both men and women.Histogen says the study was initiated to evaluate the safety and efficacy of HSC, and also produced “hair growth effects in patients with diffuse hair loss.” The company’s disclosure triggered a flurry of hopeful comments on Xconomy, beginning with a post by “Hope for Baldness,” who linked to Histogen’s PDF file and wrote, “I always read comments here and never post but I was force to post this.Even if the company continues to show positive results, it will be years before Histogen could bring its HSC treatment to market.In response to my query about Histogen’s timeline for development, the company passed along an email from CEO Naughton: “We anticipate pivotal trials in the U.S. or Asia will begin next year.As it is Histogen’s business model to bring each of its product applications to market through partnerships with leaders in different industries and geographic locations, strategy for future clinical trials of HSC will be largely dependent upon the regions of interest for such partners.